Bronchiectasis and the risk of cardiovascular disease: A population-based study

Thorax

Volumn 72, Issue 2, 2017, Pages 161-166

  Navaratnam, Vidya ^a,b,c   Millett, Elizabeth R C ^b   Hurst, John R ^d   Thomas, Sara L ^b   Smeeth, Liam ^b   Hubbard, Richard B ^a   Brown, Jeremy ^d   Quint, Jennifer K ^b,e  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRONCHIECTASIS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT CARE; POPULATION RESEARCH; PROSPECTIVE STUDY; RISK FACTOR; SMOKING HABIT; YOUNG ADULT; CARDIOVASCULAR DISEASES; COMPLICATION; INCIDENCE; PREVALENCE; STROKE; UNITED KINGDOM;

ADULT; AGED; BRONCHIECTASIS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; STROKE; UNITED KINGDOM;

EID: 84984601517     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-208188     Document Type: Article

References (27)

1. Ip M, Shum D, Lauder I, et al. Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis. Respir Med 1993;87:449-54.
2. Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016;47:186-93.
3. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010;104:981-5.
4. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010;65:956-62.
5. Dalleywater W, Powell HA, Hubbard RB, et al. Risk factors for cardiovascular disease in people with idiopathic pulmonary fibrosis: a population-based study. Chest 2015;147:150-6.
6. Iribarren C, Tolstykh IV, Miller MK, et al. Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. Am J Epidemiol 2012;176:1014-24.
7. Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med 2007;101:1390-7.
8. Alzeer AH, Al-Mobeirek AF, Al-Otair HA, et al. Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis. Chest 2008;133:468-73.
9. Gale NS, Bolton CE, Duckers JM, et al. Systemic comorbidities in bronchiectasis. Chron Respir Dis 2012;9:231-8.
10. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-36.
11. Zhou EH GK, Graham DJ, Ding Y, et al. Validation of stroke in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf 2013;22:234.
12. Gaist D, Wallander M, Gonzalez-Perez A, et al. Incidence of haemorrhagic stroke in the general population: validation of data from The Health Improvement Network. Pharmacoepidemiol Drug Saf 2013;22:176-82.
13. Bhattarai N, Charlton J, Rudisill C, et al. Coding, recording and incidence of different forms of coronary heart disease in primary care. PLoS ONE 2012;7: e29776.
14. Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004-2013: a population based cohort study. Eur Respir J 2016;47:186-93.
15. Ip M, Lam WK, Chan JC, et al. Systemic effects of inflammation in bronchiectasis. Respir Med 1991;85:521-5.
16. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. [The association between bronchiectasis, systemic inflammation, and tumor necrosis factor alpha]. Arch Bronconeumol 2008;44:8-14.
17. Wilson CB, Jones PW, O'Leary CJ, et al. Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998;12:820-4.
18. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988;58:249-61.
19. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-18.
20. Dregan A, Charlton J, Chowienczyk P, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 2014;130:837-44.
21. Unit TICJHS. Health Survey for England (2006). Leeds: The Information Centre, 2008.
22. Hansell A, Hollowell J, Nichols T, et al. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999;54:413-19.
23. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
24. Hollowell J. The general practice research database: quality of morbidity data. Popul Trends 1997:36-40.
25. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65:577.
26. Hill AT, Routh C, Welham S. National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care Thorax 2014;69:292-4.
27. Hill AT, Welham S, Reid K, et al. British Thoracic Society national bronchiectasis audit 2010 and 2011. Thorax 2012;67:928-30.